Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-cash Items (2019 - 2025)

Historic Non-cash Items for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $7.0 million.

  • Kymera Therapeutics' Non-cash Items fell 9529.47% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 9529.47%. This contributed to the annual value of $6.2 million for FY2024, which is 2681.72% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Non-cash Items stood at $7.0 million, which was down 9529.47% from $6.9 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Non-cash Items peaked at $246.9 million during Q4 2021, and registered a low of $1.6 million during Q1 2021.
  • Over the past 5 years, Kymera Therapeutics' median Non-cash Items value was $6.9 million (recorded in 2025), while the average stood at $48.6 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 9880.03% in 2021, then surged by 837447.47% in 2022.
  • Kymera Therapeutics' Non-cash Items (Quarter) stood at $246.9 million in 2021, then crashed by 77.35% to $55.9 million in 2022, then decreased by 11.28% to $49.6 million in 2023, then tumbled by 87.51% to $6.2 million in 2024, then increased by 13.26% to $7.0 million in 2025.
  • Its Non-cash Items was $7.0 million in Q3 2025, compared to $6.9 million in Q2 2025 and $6.6 million in Q1 2025.